TW202333775A - 一種穩定的受體激動劑的醫藥組成物、製備方法及其應用 - Google Patents
一種穩定的受體激動劑的醫藥組成物、製備方法及其應用 Download PDFInfo
- Publication number
- TW202333775A TW202333775A TW112101047A TW112101047A TW202333775A TW 202333775 A TW202333775 A TW 202333775A TW 112101047 A TW112101047 A TW 112101047A TW 112101047 A TW112101047 A TW 112101047A TW 202333775 A TW202333775 A TW 202333775A
- Authority
- TW
- Taiwan
- Prior art keywords
- pharmaceutical composition
- buffer
- active ingredient
- osmotic pressure
- pressure regulator
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210021736 | 2022-01-10 | ||
| CN2022100217361 | 2022-01-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202333775A true TW202333775A (zh) | 2023-09-01 |
Family
ID=87073306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW112101047A TW202333775A (zh) | 2022-01-10 | 2023-01-10 | 一種穩定的受體激動劑的醫藥組成物、製備方法及其應用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250170218A1 (https=) |
| EP (1) | EP4464331A4 (https=) |
| JP (1) | JP2024545887A (https=) |
| KR (1) | KR20240135785A (https=) |
| CN (1) | CN118488848A (https=) |
| AU (1) | AU2023205290A1 (https=) |
| CA (1) | CA3242599A1 (https=) |
| MX (1) | MX2024007861A (https=) |
| TW (1) | TW202333775A (https=) |
| WO (1) | WO2023131325A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12102664B2 (en) * | 2023-12-27 | 2024-10-01 | Olfactive Biosolutions, LLC | Compositions and methods for treating endocrine diseases and disorders |
| US12290550B1 (en) | 2023-12-27 | 2025-05-06 | Olfactive Ai, Inc. | Compositions and methods for treating endocrine diseases and disorders |
| WO2025191149A1 (en) * | 2024-03-15 | 2025-09-18 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising dual gip and glp-1 receptor agonist |
| WO2026007980A1 (zh) * | 2024-07-03 | 2026-01-08 | 上海海雁医药科技有限公司 | 一种mor受体激动剂的液体组合物及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101366692A (zh) * | 2007-08-15 | 2009-02-18 | 江苏豪森药业股份有限公司 | 一种稳定的艾塞那肽制剂 |
| AU2013205144B2 (en) * | 2008-06-17 | 2015-07-16 | Indiana University Research And Technology Corporation | GIP-based mixed agonists for treatment of metabolic disorders and obesity |
| CN102363633B (zh) * | 2011-11-16 | 2013-11-20 | 天津拓飞生物科技有限公司 | 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用 |
| TWI705820B (zh) * | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| CN112351994B (zh) * | 2019-04-11 | 2024-06-07 | 江苏豪森药业集团有限公司 | 一种多受体激动剂及其医药用途 |
| CN111825758B (zh) * | 2019-04-19 | 2024-11-22 | 上海翰森生物医药科技有限公司 | Glp-1和gip共激动剂化合物 |
| CN110684082B (zh) * | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
| CN113383014B (zh) * | 2019-11-15 | 2024-06-18 | 江苏豪森药业集团有限公司 | 双受体重激动剂化合物及其药物组合物 |
| EP4110800A1 (en) * | 2020-03-06 | 2023-01-04 | Sanofi | Peptides as selective gip receptor agonists |
| CN114349828B (zh) * | 2020-11-27 | 2023-12-08 | 江苏师范大学 | Glp-1/胰高血糖素受体双重激动剂及其应用 |
-
2023
- 2023-01-09 JP JP2024536467A patent/JP2024545887A/ja active Pending
- 2023-01-09 WO PCT/CN2023/071277 patent/WO2023131325A1/zh not_active Ceased
- 2023-01-09 MX MX2024007861A patent/MX2024007861A/es unknown
- 2023-01-09 EP EP23737187.7A patent/EP4464331A4/en active Pending
- 2023-01-09 AU AU2023205290A patent/AU2023205290A1/en active Pending
- 2023-01-09 CA CA3242599A patent/CA3242599A1/en active Pending
- 2023-01-09 US US18/727,070 patent/US20250170218A1/en active Pending
- 2023-01-09 KR KR1020247026226A patent/KR20240135785A/ko active Pending
- 2023-01-09 CN CN202380016384.3A patent/CN118488848A/zh active Pending
- 2023-01-10 TW TW112101047A patent/TW202333775A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN118488848A (zh) | 2024-08-13 |
| EP4464331A4 (en) | 2025-05-07 |
| CA3242599A1 (en) | 2023-07-13 |
| US20250170218A1 (en) | 2025-05-29 |
| MX2024007861A (es) | 2024-07-09 |
| JP2024545887A (ja) | 2024-12-13 |
| AU2023205290A1 (en) | 2024-07-11 |
| WO2023131325A1 (zh) | 2023-07-13 |
| KR20240135785A (ko) | 2024-09-12 |
| EP4464331A1 (en) | 2024-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202333775A (zh) | 一種穩定的受體激動劑的醫藥組成物、製備方法及其應用 | |
| TW201100093A (en) | Preparation comprising insulin, nicotinamide and an amino acid | |
| JP2024545887A5 (https=) | ||
| CN109640955B (zh) | 含有聚乙二醇洛塞那肽的药物制剂及其制备方法 | |
| EP4591875A1 (en) | Dual glp-1 and gip receptor agonist pharmaceutical composition and use thereof | |
| US20230285326A1 (en) | Epinephrine formulations | |
| CN110693861A (zh) | 一种硫酸特布他林雾化吸入用溶液制剂及其制备方法 | |
| US12343383B2 (en) | High concentration insulin formulation | |
| EP3811948B1 (en) | Glycosides for use in preventing and treating diabetic complications | |
| CN116270980A (zh) | 一种含glp-1类似物的药物组合物及其制备方法 | |
| US20140107130A1 (en) | Oral Solution Formulations of Aripiprazole | |
| TWI857310B (zh) | 酮咯酸胺丁三醇的液體組合物、其製備方法及應用 | |
| CN114848650B (zh) | 一种稳定的艾司唑仑制剂组合物及其制备方法 | |
| WO2026013454A1 (en) | Multi-dose pen of tirzepatide | |
| WO2019046952A1 (en) | SUBCUTANEOUS PHARMACEUTICAL PREPARATION COMPRISING INSULIN (S) AND ANTI-INFLAMMATORY AGENT FOR REDUCING TISSUE INFLAMMATORY RESPONSE IN DIABETIC PATIENTS | |
| WO2025190304A1 (zh) | 包含glp-1和gip双受体激动剂的药物组合物及其用途 | |
| WO2025113170A1 (zh) | 含有glp-1受体激动剂的经鼻给药的组合物及其制备方法与用途 | |
| CA2685636C (en) | Method of treatment of diabetes type 2 comprising add-on therapy to metformin | |
| CN117771347A (zh) | Glp-1类似物与胰岛素类似物药物组合物制剂及其制备方法和应用 | |
| HK40020222A (en) | Terbutaline sulfate solution preparation for aerosol inhalation and preparation method thereof | |
| CN116407614A (zh) | 一种新型三激动剂创新生物药物的稳定制剂 | |
| HK40000201B (zh) | 含有聚乙二醇洛塞那肽的药物制剂及其制备方法 | |
| CN120641091A (zh) | (s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗糖尿病和前驱糖尿病中的用途 | |
| HK40000201A (en) | Pharmaceutical preparation containing polyethylene gylcol loxenatide and preparation method thereof | |
| WO2017164776A1 (ru) | Фармацевтическая композиция глибенкламида в форме раствора для инъекций, способ ее получения и способ получения препарата глибенкламида |